Phaseline

Targets › SLC18A1

SLC18A1 (Chromaffin granule amine transporter): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2048.

[Isoform 1]: Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. (UniProt, P54219)

Open in Phaseline: the race on SLC18A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)[18F]-6F-DA
Fluorine-18 labeled dopamine analog entering cells via norepinephrine transporter (NET) an
SLC6A2, SLC18A1Phase 1PheochromocytomaNov 2048

Conditions

Pheochromocytoma (1)

Modalities

small molecule (1)

Companies

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)

Related targets

SLC6A2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.